
Product Data Sheet

Product Name: Y-9738
Cat. No.: GC32596

Chemical Properties

Cas. No. 59399-41-6

SMILES O=C(OCC)CC1=C(OCC)OC(C2=CC=C(Cl)C=C2)=N1

Formula $C_{15}H_{16}ClNO_4$ M.Wt 309.74

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Protocol**Animal experiment:**

Male Sprague-Dawley rats are used in this work. Rats (140 to 180 g) are fed a high cholesterol diet for 10 days. This diet contains 1% cholesterol, 0.2% sodium cholate and 5% olive oil. Y-9738 is orally administered to the animals once a day throughout the experimental period. All animals are starved overnight (about 20 h) after the last treatment and sacrificed by carotid incision. Blood and liver are collected for lipid analysis[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

[1]. Kobayakawa T, et al. Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent. *Atherosclerosis*. 1978 Jul;30(3):219-25.

Background

Y-9738 is a hypolipidemic agent.

Y-9738 is a hypolipidemic agent. At 100 mg/kg Y-9738 lowers the cholesterol level by 36% and clearly diminishes the intensity of the β -lipoprotein band with a tendency for the α -lipoprotein band to be intensified. Y-9738 causes a dose-dependent decrease in serum cholesterol, triglyceride and heparin-precipitable β -lipoprotein cholesterol. Furthermore, Y-9738 reduces the intensity of the β -lipoprotein band shown by electrophoresis, and increases that of the α -lipoprotein band[1].

[1]. Kobayakawa T, et al. Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent. *Atherosclerosis*. 1978 Jul;30(3):219-25.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA